{"id":68772,"date":"2026-09-02T22:19:00","date_gmt":"2026-09-02T15:19:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=68772"},"modified":"2026-09-02T22:19:00","modified_gmt":"2026-09-02T15:19:00","slug":"epivax-launches-ai-enhanced-models-for-immunogenicity-prediction","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=68772","title":{"rendered":"EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

PROVIDENCE, R.I.<\/span>, Sept. 3, 2026<\/span> \/PRNewswire\/ — EpiVax, Inc. is pleased to announce\u00a0the release of AI-enabled enhancements to ISPRI\u2122<\/b><\/a>, its proprietary in silico platform for assessing the immunogenicity risk of biotherapeutics. The release introduces an updated JanusMatrix\u2122 model, a refined tolerance-adjusted immunogenicity score, and an enhanced anti-drug antibody (ADA) prediction model designed to provide deeper insight into immunogenicity risk.\u00a0<\/p>\n

<\/div>\n

For decades, EpiVax has pioneered computational immunology through the development of advanced in silico algorithms for evaluating biotherapeutic sequences. Foundational to this work are EpiMatrix\u00ae<\/sup> and JanusMatrix\u2122, which evaluate T cell epitope content and human cross-conservation to characterize sequence-derived immunogenicity risk and immune tolerance. ISPRI\u2122 brings these tools together with other extensively validated methods to assess immunogenicity risk across candidate and impurity sequences.\u00a0<\/p>\n

JanusMatrix\u2122 2.1<\/u><\/b>
JanusMatrix\u2122 2.1 applies AI to improve the prediction of immune tolerance by weighting human epitope cross-conservation based on expression and prevalence data. The result is a more precise characterization of therapeutic epitopes and their tolerance profiles.\u00a0<\/p>\n

JanusMatrix-Adjusted EpiMatrix Score<\/u><\/b>
Building on JanusMatrix 2.1, EpiVax has introduced a new immunogenicity score designed to align more closely with clinical immunogenicity outcomes. The JanusMatrix-Adjusted EpiMatrix (JAX) score incorporates JanusMatrix tolerance potential directly into EpiMatrix scores, providing insight into intrinsic effector epitope density and a more biologically-informed assessment of sequence-derived immunogenicity risk across therapeutic modalities.\u00a0<\/p>\n

ADA 2.2<\/u><\/b>
EpiVax has also updated its ADA prediction model with the release of ADA 2.2. The enhanced model combines epitope-based measures with biophysical attributes and mode of action criteria to provide another assessment of antibody immunogenicity risk, trained specifically leveraging a diverse set of clinical monoclonal antibodies. ADA 2.2 demonstrates a stronger correlation between predicted and clinically observed immunogenicity, providing greater confidence in risk interpretation alongside the JAX score.<\/p>\n

These newly available features further strengthen EpiVax’s best-in-class immunoinformatics capabilities, improving the relevance and predictive value of in silico immunogenicity risk assessments. The enhancements align closely with recent FDA initiatives advancing the adoption of human-relevant New Approach Methodologies (NAMs), while helping sponsors identify immune liabilities, protect asset value, and de-risk development programs.\u00a0<\/p>\n

About EpiVax<\/u><\/b>
EpiVax<\/a>\u202fpartners with biologic developers to manage immunogenicity risk throughout the product lifecycle.\u202fLeveraging\u202fdeep scientific\u202fexpertise\u202fto apply industry-leading in silico analyses and in vitro approaches, insights\u202ffrom actionable data\u202fhelp our partners reduce uncertainty, mitigate risk, and use resources more efficiently while building regulatory-ready strategies for safer, more effective therapies.\u00a0<\/p>\n

Media Contact:<\/u><\/b>
Sarah Moniz, Director of Business Development & Marketing
smoniz@epivax.com<\/a>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

PROVIDENCE, R.I.<\/span>, Sept. 3, 2026<\/span> \/PRNewswire\/ — EpiVax, Inc. is pleased to announce\u00a0the release of AI-enabled enhancements to ISPRI\u2122<\/b><\/a>, its proprietary in silico platform for assessing the immunogenicity risk of biotherapeutics. The release introduces an updated JanusMatrix\u2122 model, a refined tolerance-adjusted immunogenicity score, and an enhanced anti-drug antibody (ADA) prediction model designed to provide deeper insight into immunogenicity risk.\u00a0<\/p>\n

<\/div>\n

For decades, EpiVax has pioneered computational immunology through the development of advanced in silico algorithms for evaluating biotherapeutic sequences. Foundational to this work are EpiMatrix\u00ae<\/sup> and JanusMatrix\u2122, which evaluate T cell epitope content and human cross-conservation to characterize sequence-derived immunogenicity risk and immune tolerance. ISPRI\u2122 brings these tools together with other extensively validated methods to assess immunogenicity risk across candidate and impurity sequences.\u00a0<\/p>\n

JanusMatrix\u2122 2.1<\/u><\/b>
JanusMatrix\u2122 2.1 applies AI to improve the prediction of immune tolerance by weighting human epitope cross-conservation based on expression and prevalence data. The result is a more precise characterization of therapeutic epitopes and their tolerance profiles.\u00a0<\/p>\n

JanusMatrix-Adjusted EpiMatrix Score<\/u><\/b>
Building on JanusMatrix 2.1, EpiVax has introduced a new immunogenicity score designed to align more closely with clinical immunogenicity outcomes. The JanusMatrix-Adjusted EpiMatrix (JAX) score incorporates JanusMatrix tolerance potential directly into EpiMatrix scores, providing insight into intrinsic effector epitope density and a more biologically-informed assessment of sequence-derived immunogenicity risk across therapeutic modalities.\u00a0<\/p>\n

ADA 2.2<\/u><\/b>
EpiVax has also updated its ADA prediction model with the release of ADA 2.2. The enhanced model combines epitope-based measures with biophysical attributes and mode of action criteria to provide another assessment of antibody immunogenicity risk, trained specifically leveraging a diverse set of clinical monoclonal antibodies. ADA 2.2 demonstrates a stronger correlation between predicted and clinically observed immunogenicity, providing greater confidence in risk interpretation alongside the JAX score.<\/p>\n

These newly available features further strengthen EpiVax’s best-in-class immunoinformatics capabilities, improving the relevance and predictive value of in silico immunogenicity risk assessments. The enhancements align closely with recent FDA initiatives advancing the adoption of human-relevant New Approach Methodologies (NAMs), while helping sponsors identify immune liabilities, protect asset value, and de-risk development programs.\u00a0<\/p>\n

About EpiVax<\/u><\/b>
EpiVax<\/a>\u202fpartners with biologic developers to manage immunogenicity risk throughout the product lifecycle.\u202fLeveraging\u202fdeep scientific\u202fexpertise\u202fto apply industry-leading in silico analyses and in vitro approaches, insights\u202ffrom actionable data\u202fhelp our partners reduce uncertainty, mitigate risk, and use resources more efficiently while building regulatory-ready strategies for safer, more effective therapies.\u00a0<\/p>\n

Media Contact:<\/u><\/b>
Sarah Moniz, Director of Business Development & Marketing
smoniz@epivax.com<\/a>\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-68772","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/68772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68772"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/68772\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}